Clinical efficacy of donepezil combined with nerve growth factor in the treatment of patients with Parkinson’s disease dementia and its impact on adiponectin and soluble tumor necrosis factor-alpha receptor-1

Combined regimen of donepezil and NGF is more effective than donepezil monotherapy in improving cognitive function, neurological function, and severity of the condition of patients with PDD, and is associated with the suppression of the inflammatory response without a significant increase in the incidence of adverse reactions. The study provides a basis for the clinical application of the combined regimen, but it still needs to be confirmed by more basic and clinical research.